Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Teruaki Shiomi,Satoshi Ushijima,Emi Yamada,Sakae Tanaka,Yeong-Wook Song,Hiroyuki Izutsu,Yoshiya Tanaka,Yuichiro Kaneko,Mitsuhiro Rokuda,Tsutomu Takeuchi,Yoshihiro Nakashima,Atsushi Kawakami,Yi-Hsing Chen

doi:10.1186/s13075-020-02247-3

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Highlights

Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c
The CI numbers in the table below the graph are correct, but the upper and lower limit bars plotted on the graph are incorrect
* Correspondence: tsutake@z5.keio.jp These data were presented in part as a poster at the 2019 ACR/ARHP Annual Meeting, November 8–13, 2019, Atlanta, GA and as an oral presentation at the 2019 JCRA Annual Meeting, November 30, 2019, Nagoya, Aichi. †Tsutomu Takeuchi and Yoshiya Tanaka contributed to this work. 1Keio University School of Medicine, Tokyo, Japan Full list of author information is available at the end of the article

Summary

Introduction

Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c. Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Results

Conclusion